ATAI trades 4.6% below Wall Street's consensus target of $7.69.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ATAI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Atai Beckley Inc. (ATAI) has a Wall Street consensus price target of $7.69, based on estimates from 8 covering analysts. With the stock currently trading at $7.35, this represents a potential upside of +4.6%. The company has a market capitalization of $2.72B.
Analyst price targets range from a low of $7.45 to a high of $8.00, representing a 7% spread in expectations. The median target of $7.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 0 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, ATAI trades at a trailing P/E of -2.5x. Analysts expect EPS to grow +76.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CMPSCOMPASS Pathways plc | $1.9B | $13.75 | $18.63 | +35.5% | Buy | — | 15 |
 MNMDMind Medicine (MindMed) Inc. | $3.2B | $42.79 | $20.00 | -53.3% | Buy | — | 1 |
 CYBNCybin Inc. | $304M | $6.09 | — | — | Buy | — | 4 |
 SILOSilo Pharma, Inc. | $2M | $1.77 | — | — | — | — | — |
 ENVBEnveric Biosciences, Inc. | $934324 | $1.56 | — | — | — | — | — |
 JAZZJazz Pharmaceuticals plc | $14.8B | $234.88 | $289.50 | +23.3% | Buy | 9.4x | 48 |
 INVAInnoviva, Inc. | $1.5B | $20.24 | $38.00 | +87.7% | Buy | 8.2x | 10 |
 PRAXPraxis Precision Medicines, Inc. | $7.9B | $282.12 | $603.83 | +114.0% | Buy | — | 18 |
 ACADACADIA Pharmaceuticals Inc. | $4.4B | $25.43 | $33.83 | +33.0% | Buy | 41.1x | 37 |
 AXSMAxsome Therapeutics, Inc. | $10.0B | $193.45 | $282.53 | +46.0% | Buy | — | 26 |
Quick answers to the most common questions about buying ATAI stock.
The consensus price target for ATAI is $7.69, close to the current price of $7.35 (4.6% implied move). Based on 8 analyst estimates, the stock appears fairly valued near current levels.
ATAI has a consensus rating of "Hold" based on 8 Wall Street analysts. The rating breakdown is mixed, with 8 Hold ratings making up the largest segment. The consensus 12-month price target of $7.69 implies 4.6% upside from current levels.
ATAI's current price is $7.35 with a consensus target of $7.69 (4.6% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $8 for ATAI, while the most conservative target is $7.45. The consensus of $7.69 represents the median expectation. These targets typically reflect 12-month expectations.
ATAI is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 8 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ATAI stock forecast based on 8 Wall Street analysts shows a consensus price target of $7.69, with estimates ranging from $7.45 (bear case) to $8 (bull case). The median consensus rating is "Hold".
ATAI appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $7.69 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ATAI analyst price targets range from $7.45 to $8, a 7% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7.69 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.